Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 3Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 165fludarabine phosphate 110Peripheral Blood Stem Cell Transplantation 94Mycophenolic Acid 88Whole-Body Irradiation 81Etoposide 81Tacrolimus 73Busulfan 68Melphalan 67Filgrastim 66fludarabine 62Radiotherapy 56Doxorubicin 54Cyclosporine 54Rituximab 50Brentuximab Vedotin 48Antilymphocyte Serum 47Granulocyte Colony-Stimulating Factor 42Vinblastine 41Methotrexate 38Dacarbazine 37Cytarabine 35Gemcitabine 34Nivolumab 30Bleomycin 29Carmustine 28Vincristine 25Prednisone 25Sirolimus 24Bendamustine Hydrochloride 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hodgkin Disease × pegylated granulocyte colony-stimulating factor, human × Clear all
NCT01169636 2021-01-06

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Completed
62 enrolled 13 charts
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡